Расскажите друзьям в Москве о нашей вакансии hh.ru/vacancy/135903781

Channel
Цифровая медицина
@digitalmedicine
On this record: Growth · Engagement · Reactions · Posts · Citations · Cite this entry
3,337subscribers
-6 since we began measuring on 6 August 2026
Risers and fallers across the register · movement among entries of 3,162–10,000.
Register entry
| Telegram ID | -1001110290578 |
|---|---|
| Type | Channel |
| Username | @digitalmedicine |
| Created | 22 February 2017 — measured — cross-checked against a third-party dataset (ext.tg_channel) |
| First recorded | 6 August 2026 |
| Last confirmed live | 25 August 2026 |
| Measurements held | 7 |
| Confirmed unchanged | 1 time, most recently 25 August 2026 |
| On Telegram | t.me/digitalmedicine |
Growth
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 25 Aug 2026, 18:23 | 3,337 | +1 |
| 22 Aug 2026, 17:58 | 3,336 | -3 |
| 16 Aug 2026, 02:07 | 3,339 | -1 |
| 9 Aug 2026, 11:01 | 3,340 | -2 |
| 6 Aug 2026, 10:20 | 3,342 | -1 |
| 6 Aug 2026, 04:46 | 3,343 | no change |
| 6 Aug 2026, 02:35 | 3,343 | first reading |
Engagement
20 posts held, back to 7 July 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 3 pagesof Telegram’s post history, 20 posts per page.
- ERR · 30 days
- 5.80%
- avg views ÷ 3,337 subscribers
- Avg views / post
- 194
- 2 posts measured
- Reaction rate
- 0.435%
- reactions ÷ views · ER floor
- Posts in window
- 2
- of 20 held
ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.
ER is defined industry-wide as (forwards + reactions + comments) ÷ views— note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate. It is computed over the 1 of 2 measured posts that carry a reaction reading, and over those same posts' views.
| Window | Rolling 30 days · latest post in window 4 August 2026 |
|---|---|
| Posts held | 20 (7 July 2026 – 4 August 2026) |
| Views total | 387 |
| Reactions total | 1 |
| Forwards / comments | not exposed by the public surface — not measured, not estimated |
| Readings taken | 7 Aug 2026, 23:27 UTC |
Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.
Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.
Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.
Reaction mix
4 reactions across 4 posts, in 3 distinct kinds. The most used accounts for 50.0% of them.
| Reaction | Count | Share | Share, drawn |
|---|---|---|---|
| ❤ | 2 | 50.0% | |
| 🔥 | 1 | 25.0% | |
| 🤬 | 1 | 25.0% |
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 6 of the 20 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 4reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 20 most recent posts we hold, published 7 July 2026 to 4 August 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
Recent posts
Зимой этого года одна российская фармкомпания, несмотря на наши предупреждения, провела тендер по ведению каналов в Телеграме. Предположу, что в ближайшие часы менеджеров этой фармкомпании можно будет встретить в очереди на Верхнем Ларсе, вместе с теми, кому они отдали тот тендер 😅
🤬1
БАРИЦИТИНИБ ПОШЕЛ ЧЕРЕЗ СУД «Биохимик» получил принудительную лицензию на барицитиниб. Суд решил, что компания доказала существенное экономическое преимущество своего процесса. В решении указано, что технология дает более чистый продукт, повышает выход и снижает расход сырья. Патент на оригинальное изобретение действует до декабря 2033 года. Из зарегистрированных в России дженериков цену пока объявил только «Промом…
У НИВОЛУМАБА ПОЯВИЛСЯ НАШ АНАЛОГ В России зарегистрировали первый биоаналог ниволумаба - препарат «Нивокад» от Biocad. Это аналог «Опдиво», с теми же показаниями: от меланомы и рака легкого до лимфомы Ходжкина и опухолей головы и шеи. Выпуск наладили на площадках в Стрельне и Зеленограде. Оригинальный ниволумаб уже работает в ОМС и программе ВЗН, а новый аналог в перечень ЖНВЛП пока не вошел.
НОВЫЙ ПРЕПАРАТ ДЛЯ НМРЛ ПОШЕЛ В КИ Минздрав разрешил I фазу клинических испытаний российского препарата GNR-110 для лечения метастатического неплоскоклеточного немелкоклеточного рака легкого. Препарат будут изучать в первой линии вместе с таргетной и химиотерапией. В исследование до июня 2029 года включат до 140 пациентов в 34 центрах по стране. Смотрят фармакокинетику, безопасность и иммуногенность.
НАШ БИОЛОГИЧЕСКИЙ ЗАСВЕТИЛСЯ В APLAR Олокизумаб от Р-Фарм включили в обновленные рекомендации Азиатско-Тихоокеанской лиги ассоциаций ревматологов по лечению ревматоидного артрита. Для российского биологического препарата это случилось впервые. В основу вошли данные исследований CREDO 1 и CREDO 3 по эффективности и безопасности. Рекомендации 2026 года охватывают оценку активности болезни, терапию, инфекционную безоп…
БАРИЦИТИНИБ ПУСТИЛИ ПО ЛИЦЕНЗИИ Суд в Подмосковье обязал правообладателя патента на барицитиниб выдать «Биохимику» простую лицензию. Компания сможет законно производить, вводить в оборот и применять препараты с этим МНН в России до конца срока патента. Платеж по лицензии составит 2,1% от фактической выручки. В России уже зарегистрированы четыре препарата с барицитинибом, а у «Промомеда» цена упаковки 4 мг на 28 таб…
ГОСЗАКУПКИ ЛЕКАРСТВ РЕЗКО ВЫРОСЛИ Объем госзакупок лекарств вырос на 43%. Цифра заметная. Для рынка это уже не косметика, а вполне ощутимый разворот.
У ДИАБЕТА И ОЖИРЕНИЯ НОВЫЙ КАНДИДАТ В России запустили клиническое исследование препарата компании АстраЗенека для лечения сахарного диабета и ожирения. Пока это не новый пункт в назначениях, а этап проверки. Но новость для практики заметная: в поле зрения сразу две проблемы, которые часто ходят парой.
❤1
ГАМАЛЕЯ ВЗЯЛАСЬ ЗА СВОЙ GLP-1 Центр им. Гамалеи до декабря 2026 года должен создать главный банк модифицированных клеток E. coli, которые вырабатывают инкретин GLP-1. Речь о заделе для нового средства при диабете 2 типа. Идея не в очередном уколе, а в живых пробиотиках: после приема внутрь они должны работать прямо в кишечнике и давать более долгий эффект.
🔥1
Запустили рекламу в Яндексе на менеджеров биг фармы, ссылка ведет на наш калькулятор partner.doktornarabote.ru/calc
Цифровая медицина pinned a photo
Showing the 12 most recent of 20 posts we hold for @digitalmedicine. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Citation-graph rank
Citation-graph rank — 796,180 of 1,621,120entries in the measured graph. A weighted position computed from the forward and mention edges below — republished posts weigh more than named mentions — and recomputed periodically, over the whole graph. Published only as this ordinal position, never as a score: a position is a fact, and a score printed beside one channel’s name would read as a verdict this register does not make. The two counts beneath stay separate for the same reason mentions are never summed with forwards anywhere else on this page — a named-by count costs nothing to manufacture. The top 100 by this measure, or how it is computed.
Mentions
Named by 1 registered channel — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.
Named by
Channels on the register whose posts name this channel's handle.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
Cite this entry
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 25 August 2026 — this entry's latest reading, not the date you are reading this.
“Цифровая медицина” (@digitalmedicine), 3,337 subscribers as measured 25 August 2026. Telegram Register, tgregister.com/channel/digitalmedicine.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.